Oral Mucositis Thera
Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years: P&S Market Research
April 06, 2018 01:30 ET | P&S Market Research
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Oral Mucositis Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Oral Mucositis...
Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM); Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM
January 03, 2018 07:00 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint...
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
December 27, 2017 07:30 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging...
Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis
December 21, 2017 07:30 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up...
Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value
December 18, 2017 07:30 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today is pleased to provide an update on the...
Innovation Pharmaceuticals Granted European Patent for Brilacidin in the Prevention of Oral Mucositis
December 12, 2017 08:00 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the European Patent...
Innovation Pharmaceuticals Reports Positive Topline Results from Phase 2 Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients; Company Targets a Therapeutic Leadership Position in Global OM Market
December 11, 2017 07:00 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented successful topline results...
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2b Study of Oral Prurisol for Psoriasis
November 30, 2017 08:00 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has...
Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
November 16, 2017 08:00 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide additional...
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2 Trial of Brilacidin for Preventing Oral Mucositis in Cancer Patients
October 02, 2017 07:00 ET | Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has...